aTyr Pharma, Inc.(US:ATYR) Prnewswire·2025-11-21 13:45Core Viewpoint - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to misleading statements about the efficacy of its drug Efzofitimod, which led to significant stock price decline after the truth was revealed [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for aTyr investors affected by alleged securities fraud between November 7, 2024, and September 12, 2025 [1]. - Defendants allegedly provided positive statements while concealing adverse facts about Efzofitimod's efficacy, particularly its ability to allow patients to taper steroid usage [2]. - The truth emerged on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to a drastic stock price drop from $6.03 to $1.02, a decline of 83.2% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until December 8, 2025, to request to be appointed as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].